BioNTech SE Stock price

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
92.99 USD +0.55% Intraday chart for BioNTech SE -3.44% -11.89%
Sales 2023 * 4.19B 4.55B Sales 2024 * 3.07B 3.34B Capitalization 20.33B 22.09B
Net income 2023 * 1.07B 1.16B Net income 2024 * 138M 150M EV / Sales 2023 * 0.69 x
Net cash position 2023 * 17.44B 18.95B Net cash position 2024 * 17.97B 19.52B EV / Sales 2024 * 0.77 x
P/E ratio 2023 *
19.2 x
P/E ratio 2024 *
420 x
Employees 5,700
Yield 2023 *
-
Yield 2024 *
-
Free-Float 86.48%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.55%
1 week-3.44%
Current month+4.53%
1 month+1.44%
3 months-10.22%
6 months-14.72%
Current year-11.89%
More quotes
1 week
91.47
Extreme 91.47
96.68
1 month
87.90
Extreme 87.9001
97.50
Current year
87.90
Extreme 87.9001
114.70
1 year
87.90
Extreme 87.9001
136.92
3 years
87.90
Extreme 87.9001
464.00
5 years
12.53
Extreme 12.525
464.00
10 years
12.53
Extreme 12.525
464.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 08-06-01
Founder 57 08-06-01
Director of Finance/CFO 60 21-06-30
Members of the board TitleAgeSince
Director/Board Member 69 21-12-31
Director/Board Member 67 08-06-01
Chairman 53 08-06-01
More insiders
Date Price Change Volume
24-03-18 92.99 +0.55% 459,241
24-03-15 92.48 -0.46% 645,461
24-03-14 92.91 -1.11% 638,368
24-03-13 93.95 -1.86% 565,946
24-03-12 95.73 -0.59% 411,429

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
85.53 EUR
Average target price
116.4 EUR
Spread / Average Target
+36.08%
Consensus
  1. Stock
  2. Equities
  3. Stock BioNTech SE - Nasdaq